2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone | 485334-41-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone
• 英文别名: 2-[(4-Ethyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]-1-phenylethanone
• CAS: 485334-41-6
• 化学式: C₁₈H₁₇N₃OS
• 分子量: 323.418
• InChiKey: GFQOBDVRSFYXCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  73.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 以89%的产率得到2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone oxime
  参考文献：
  名称：

  New nitric oxide donating 1,2,4-triazole/oxime hybrids: Synthesis, investigation of anti-inflammatory, ulceroginic liability and antiproliferative activities

  摘要：

  A series of novel nitric oxide (NO) donating triazole/oxime hybrids was prepared and evaluated for their anti-inflammatory activity. Most of the tested compounds showed significant anti-inflammatory activity using carrageenan-induced rat paw edema method compared to indomethacin. Calculation of the ulcer indices and histopathological investigation indicated that the prepared NO-donating oximes exhibited less ulcerogenicity compared to their intermediate ketones and indomethacin. The NO-donating oxime 6i revealed significant activity against renal cancer A498 cell lines with 50.52 cell growth inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.022
• 作为产物：
  描述：

  苯甲酰肼 在 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 2-(4-ethyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-1-phenylethanone
  参考文献：
  名称：

  New nitric oxide donating 1,2,4-triazole/oxime hybrids: Synthesis, investigation of anti-inflammatory, ulceroginic liability and antiproliferative activities

  摘要：

  A series of novel nitric oxide (NO) donating triazole/oxime hybrids was prepared and evaluated for their anti-inflammatory activity. Most of the tested compounds showed significant anti-inflammatory activity using carrageenan-induced rat paw edema method compared to indomethacin. Calculation of the ulcer indices and histopathological investigation indicated that the prepared NO-donating oximes exhibited less ulcerogenicity compared to their intermediate ketones and indomethacin. The NO-donating oxime 6i revealed significant activity against renal cancer A498 cell lines with 50.52 cell growth inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.022

文献信息

• [EN] PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES<br/>[FR] UTILISATION PHARMACEUTIQUE DE 1,2,4-TRIAZOLES SUBSTITUEES
  申请人：NOVO NORDISK AS

  公开号：WO2004089367A1

  公开（公告）日：2004-10-21

  The use of substituted 1,2,4-triazoles for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11 βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of substituted 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11 βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  已描述了使用取代的1,2,4-三唑来调节11β-羟基甾醇脱氢酶1（11βHSD1）活性以及将这些化合物用作药物组合物的用途。还描述了一类新型的取代的1,2,4-三唑，它们在治疗中的用途，包含这些化合物的药物组合物，以及它们在制造药物中的用途。这些化合物是11βHSD1活性的调节剂，更具体地是抑制剂，并且可能在治疗、预防和/或预防一系列需要降低细胞内活性糖皮质激素浓度的医学疾病中有用。
• Pharmaceutical use of substituted 1,2,4-triazoles
  申请人：Andersen Sune Henrik

  公开号：US20060100235A1

  公开（公告）日：2006-05-11

  The use of substituted 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of substituted 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  使用替代1,2,4-三唑来调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，并将这些化合物用作制药组合物已被描述。还描述了一种新的替代1,2,4-三唑类，它们在治疗中的用途，包含这些化合物的制药组合物，以及它们在制药中的用途。这些化合物是11βHSD1活性的调节剂，更具体地是抑制剂，可能在治疗、预防和/或预防一系列医学疾病中有用，其中降低细胞内活性糖皮质激素的浓度是可取的。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。
• Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
  申请人：NOVO NORDISK A/S

  公开号：EP1862181A2

  公开（公告）日：2007-12-05

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和降压药组成的联合疗法，可用于治疗、预防和降低胰岛素抵抗、血脂异常、肥胖、高血压及其他相关疾病和紊乱的发病风险。
• Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
  申请人：Kampen Tejlgaard Gita Camilla

  公开号：US20060094699A1

  公开（公告）日：2006-05-04

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。